Condition: Methylmalonic Acidemia · Sponsor: ModernaTX, Inc.
The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
This description comes directly from the study's public registry record.
Moderna WeCare Team · 1-866-663-3762 · WeCareClinicalTrials@modernatx.com
Always discuss trial participation with your own doctor first.
| UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| Lucile Packard Children's Hospital at Stanford | Palo Alto, California, United States | Recruiting |
| Altman Clinical and Translational Research Institution | San Diego, California, United States | Recruiting |
| Stollery Children's Hospital University of Alberta | Edmonton, Alberta, Canada | Recruiting |
| Hospital For Sick Children | Toronto, Ontario, Canada | Recruiting |
| Hôpital Necker - Enfants Malades APHP | Paris, France | Recruiting |
| Erasmus MC | Rotterdam, Netherlands | Recruiting |
| Universitair Medisch Centrum Utrecht | Utrecht, Netherlands | Recruiting |
| Hospital Universitario Cruces | Barakaldo, Vizcaya, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Birmingham Children's Hospital NHS Foundation Trust | Birmingham, United Kingdom | Terminated |
| Royal Manchester Childrens Hospital | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05295433